Clinical-Stage Companies / Keymed Biosciences

Keymed Biosciences

Pre-Approval PRO BETA

Total Trials

Phase 3

Phase 2

Recruiting

524

Score

Pipeline by Phase

Phase 3

Phase 2

Phase 1

Therapeutic Focus

Atopic Dermatitis Healthy Asthma Chronic Rhinosinusitis With Nasal Polyposis Allergic Rhinitis

Clinical Trials (53)

NCT06495229 Phase 3 ACTIVE NOT RECRUITING

Study of CM310 in Adolescent Subjects With Atopic Dermatis

Started: 8/2/2024

NCT06277765 Phase 3 COMPLETED

Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

Started: 3/21/2024

NCT07181239 Phase 3 NOT YET RECRUITING

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Started: 9/1/2025

NCT07106372 Phase 3 NOT YET RECRUITING

A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Started: 9/1/2025

NCT06424470 Phase 3 ACTIVE NOT RECRUITING

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Started: 6/25/2024

NCT06956196 Phase 3 NOT YET RECRUITING

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Started: 5/1/2025

NCT05908032 Phase 3 COMPLETED

Study of CM310 in Subjects With Allergic Rhinitis

Started: 8/10/2023

NCT05265923 Phase 3 COMPLETED

A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis

Started: 4/22/2022

NCT05436275 Phase 3 COMPLETED

A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2）

Started: 8/9/2022

NCT07166211 Phase 2 RECRUITING

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Started: 11/27/2025

NCT07039578 Phase 2 RECRUITING

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Started: 7/25/2025

NCT07230483 Phase 2 RECRUITING

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

Started: 12/1/2025

NCT07011524 Phase 2 RECRUITING

Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

Started: 8/19/2025

NCT06947980 Phase 2 RECRUITING

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Started: 6/19/2025

NCT06525597 Phase 2 RECRUITING

Study of Stapokibart Injection in Patients With Allergic Rhinitis

Started: 9/30/2024

NCT05775042 Phase 2 RECRUITING

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

Started: 5/8/2023

NCT07519577 Phase 2 NOT YET RECRUITING

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）

Started: 5/31/2026

NCT06830395 Phase 2 NOT YET RECRUITING

Study of CM313 in Subject With IgA Nephropathy

Started: 9/1/2025

NCT06980142 Phase 2 NOT YET RECRUITING

A Study of CM512 in Subjects With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Started: 6/20/2025

NCT06594146 Phase 2 ACTIVE NOT RECRUITING

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

Started: 11/11/2024

NCT06930612 Phase 2 NOT YET RECRUITING

A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-1）

Started: 5/16/2025

NCT06791772 Phase 2 NOT YET RECRUITING

Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)

Started: 2/1/2025

NCT05908721 Phase 2 COMPLETED

Study of CM310 in Patients With Allergic Rhinitis

Started: 8/23/2023

NCT05579925 Phase 2 COMPLETED

A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis

Started: 10/7/2022

NCT04893707 Phase 2 COMPLETED

The Study of CM310 in Patients With Atopic Dermatitis

Started: 6/7/2021

NCT05131464 Phase 2 COMPLETED

The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Started: 11/30/2021

NCT05715320 Phase 2 COMPLETED

Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis

Started: 3/10/2023

NCT06372678 Phase 2 NOT YET RECRUITING

Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Started: 6/30/2024

NCT05186909 Phase 2 COMPLETED

A Study of CM310 in Subjects With Moderate to Severe Asthma

Started: 1/12/2022

NCT04805398 Phase 2 COMPLETED

Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1)

Started: 4/6/2021

NCT04805411 Phase 2 COMPLETED

Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Started: 2/24/2021

NCT07292688 Phase 1 RECRUITING

Study of CM383 in Healthy Subjects

Started: 1/1/2026

NCT07175493 Phase 1 RECRUITING

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

Started: 11/18/2025

NCT07019779 Phase 1 RECRUITING

Study of CM518D1 in Patients With Advanced Solid Tumors

Started: 6/27/2025

NCT07175506 Phase 1 RECRUITING

Study of CM559 in Healthy Subjects

Started: 9/1/2025

NCT06792019 Phase 1 RECRUITING

Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness

Started: 3/25/2025

NCT05263960 Phase 1 RECRUITING

A Study of CM350 in Patients With Advanced Solid Tumors

Started: 4/21/2022

NCT06619613 Phase 1 RECRUITING

A Study of CM383 in Patients With Alzheimer's Disease Related Mild Cognitive Impairment and Mild Alzheimer's Disease

Started: 11/8/2024

NCT06412185 Phase 1 RECRUITING

Single Dose Escalation Study of CM383 in Healthy Volunteers

Started: 5/28/2024

NCT05299424 Phase 1 RECRUITING

A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma

Started: 8/9/2022

NCT06553209 Phase 1 COMPLETED

Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

Started: 9/2/2024

NCT06791824 Phase 1 NOT YET RECRUITING

Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia

Started: 3/1/2025

NCT04805307 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Started: 12/24/2020

NCT05324137 Phase 1 COMPLETED

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Started: 7/11/2022

NCT05715333 Phase 1 COMPLETED

Study of CM326 Injection in Healthy Subjects

Started: 3/21/2023

NCT05186285 Phase 1 COMPLETED

Single Ascending Dose Study of CM338 in Healthy Volunteers

Started: 12/11/2021

NCT05371379 Phase 1 COMPLETED

Multiple Ascending Dose Study of CM338 in Healthy Volunteers

Started: 5/24/2022

NCT06162507 Phase 1 COMPLETED

Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Started: 12/22/2023

NCT05702450 Phase 1 COMPLETED

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

Started: 3/22/2023

NCT06161090 Phase 1 COMPLETED

Study of CM310 in Healthy Subjects

Started: 9/3/2019

NCT05171348 Phase 1 COMPLETED

A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects

Started: 1/7/2022

NCT04842201 Phase 1 COMPLETED

Single Ascending Dose Study of CM326 in Healthy Volunteers

Started: 4/13/2021

NCT04893941 Phase 1 COMPLETED

Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)

Started: 7/21/2020

Drug Candidates

CM512 injection placebo CM512 CM383 CM336 Injection CM336 Injection(Low dose group) CM336 Injection(High dose group) CM518D1 CM310 Placebo

Activity Status: Active

Last Trial Started: 5/31/2026

Last Trial Ended: 9/12/2025

Trials (12 months): 15

Completed Trials: 24

Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.